Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
“Limited treatment options calls for the development of new drugs that are effective against this devastating infection,” Ghannoum said. “We hope that we contributed in some way towards the development of new drugs.”
The Latest on: Antifungal
Antifungal resistance could lead to ‘global food shortages’
on May 21, 2018 at 5:20 am
Researchers warn that growing levels of resistance to antifungal treatments could result in disease outbreaks that hit global food security. An international team led by scientists from Imperial College London and the University of Exeter have suggested ... […]
Antifungal resistance is getting worse
on May 18, 2018 at 5:35 pm
If you're a human with a vagina, you probably know a thing or two about yeast infections-and how they're a total b*tch. Even b*tchier: they’re getting harder and harder to treat thanks to the threat of antifungal resistance. On Friday, Newsweek called ... […]
Antifungal drug resistance is a ticking global time-bomb
on May 18, 2018 at 2:44 pm
There’s a whole lot of fungus amongst us coming with resistance to the drugs with which we resist them. The rate at which pathogenic fungi are resisting commonly used antifungal agents is, as researchers suggest this week, “unprecedented.” One of the ... […]
Antifungal Resistance Is Getting Worse—And It Could Make Treating Yeast Infections Even More Hellish
on May 18, 2018 at 2:33 pm
Resistance to antifungal drugs is on the rise, according to a new review published in the journal Science. Researchers believe resistance to medications called azoles, which are used to treat yeast infections, is particularly concerning to public health. […]
Humans are getting more resistant to antifungal drugs – as well as antibiotics
on May 18, 2018 at 8:29 am
Scientists have warned that levels of resistance to fungal infection treatments are increasing, which could lead to disease outbreaks and could affect food security on a global scale. An international team of researcher led by scientists from Imperial ... […]
Growing resistance to antifungal drugs 'a global issue'
on May 17, 2018 at 4:36 pm
These are external links and will open in a new window Scientists are warning that levels of resistance to treatments for fungal infections are growing, which could lead to more outbreaks of disease. Intensive-care and transplant patients and those with ... […]
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
on May 17, 2018 at 11:38 am
1 MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London W2 1PG, UK. 2 Department of Biointeractions and Crop Protection, Rothamsted Research, Harpenden AL5 2JQ, UK. 3 Institute of Microbiology ... […]
Resistance to antifungal drugs could lead to disease and global food shortages
on May 17, 2018 at 11:06 am
Growing levels of resistance to antifungal treatments could lead to increased disease outbreaks and affect food security around the world. An international team, led by researchers from Imperial College London and the University of Exeter, warns that ... […]
U.K. prof says his antifungal compound could prevent global pandemic
on May 10, 2018 at 5:13 am
A University of Sussex Professor believes his 40 years of research into a plant enzyme may help prevent cereal blight in major crops and a potential global pandemic caused by Candida auris. […]
UK Professor says his antifungal compound could prevent global pandemic
on May 10, 2018 at 3:57 am
A University of Sussex Professor believes his 40 years of research into a plant enzyme may help prevent cereal blight in major crops and a potential global pandemic caused by Candida auris. Jim Drury reports. A University of Sussex Professor believes his ... […]
via Google News and Bing News